EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
New three-year ARCADIA long-term extension data demonstrate that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis1 The findings, to be shared at EADV 2026, show that up to 91% of patients achieved at least […]
[Daily Trust] Former Vice President and ADC presidential candidate Atiku Abubakar has demanded the immediate publication of Nigeria's health agreement with the United States, following President John…
(RTTNews) - Mayne Pharma Group Limited (MYX.AX) has reached settlement with Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS), resolving the Paragraph 1V patent litigation concerning IMVEXXY…
Merck detailed some mid-stage data in a debilitating skin condition on Wednesday morning for the centerpiece of its $10.8 billion Prometheus Biosciences acquisition.
